Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Denali Therapeutics (DNLI) to $40 from $42 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
- Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
- Denali Therapeutics price target lowered to $23 from $25 at Wedbush
- Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy
- Denali Therapeutics price target raised to $34 from $32 at Baird